Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.

Abstract

We conducted the first meta-analysis to identify the predictive significance of baseline blood biomarkers (such as neutrophil to lymphocyte ratio (NLR), early alpha-fetoprotein (AFP) response, albumin-bilirubin (ALBI), AFP, platelet to lymphocyte ratio (PLR), C-reactive protein (CRP), protein induced by vitamin K absence II (PIVKA-II), and lymphocyte to monocyte ratio (LMR)) in hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs). Eligible articles were retrieved using PubMed, the Cochrane Library, EMBASE, and Google Scholar by November 24, 2022. Clinical outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and hyperprogressive disease (HPD). A total of 44 articles with 5322 patients were included in this meta-analysis. The pooled results demonstrated that patients with high NLR levels had significantly poorer OS (HR: 1.951, P<0.001) and PFS (HR: 1.632, P<0.001), lower ORR (OR: 0.484, P<0.001) and DCR (OR: 0.494, P=0.027), and higher HPD (OR: 8.190, P<0.001). The patients with high AFP levels had shorter OS (HR: 1.689, P<0.001) and PFS (HR: 1.380, P<0.001), and lower DCR (OR: 0.440, P<0.001) than those with low AFP levels, however, there was no difference in ORR (OR: 0.963, P=0.933). We also found that early AFP response was correlated with better OS (HR: 0.422, P<0.001) and PFS (HR: 0.385, P<0.001), higher ORR (OR: 7.297, P<0.001) and DCR (OR: 13.360, P<0.001) compared to non-responders. Besides, a high ALBI grade was significantly related to shorter OS (HR: 2.440, P=0.009) and PFS (HR: 1.373, P=0.022), lower ORR (OR: 0.618, P=0.032) and DCR (OR: 0.672, P=0.049) than those with an ALBI grade 1. The NLR, early AFP response, and ALBI were useful predictors of outcomes in HCC patients treated with ICIs.